The U.S. Chamber submitted comments to the European Commission as it considers revisions and updates to its General Pharmaceuticals Legislation, which is Europe’s attempt to foster innovation, improve the resiliency of the healthcare sector in Europe, bolster supply chain security, and ensure access to innovative medicines across the EU. We encouraged the EU to do a better job of rewarding and prioritizing innovation, guarantee strong IP protections for manufacturers, and preserve open and integrated global supply chains rather than attempting to cut Europe off from the global economy in healthcare. We also focused on the importance of digital health and transatlantic coordination, including for research and pandemic response and recovery.
Recommended
- International
Advancing U.S. Interests Through West Africa Partnerships
Last month in Abidjan, Cote d’Ivoire, the inaugural West Africa AmCham Business Summit marked a key moment in the United States’ renewed commercial engagement with Africa.
By Dr. Guevera Yao
- International
What Is the B7 and How Is It Connected to the G7?
By U.S. Chamber Staff
- International
Small Businesses, Big Burden: The Cost of Tariffs
By Neil Bradley - International
Assessing the U.S.-UK 'Economic Prosperity Deal'
By Marjorie Chorlins
View this online